Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thrombin time

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    112 result(s) found for: Thrombin time. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2013-002094-22 Sponsor Protocol Number: 2013MM002B Start Date*: 2013-08-29
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust (RB&HFT)
    Full Title: Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease
    Medical condition: The effect of oestrogen replacement therapy taken either orally or transdermally and observing any likely benefit of both these therapies on the risks Venous thromobembolic events and cardiovascul...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-002084-20 Sponsor Protocol Number: Version_1.0_MP_and_anticoagulants Start Date*: 2011-07-28
    Sponsor Name:Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie
    Full Title: A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex...
    Medical condition: The effect of the used IMPs should be investigated in critically ill patients and healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003464-31 Sponsor Protocol Number: BIOS-13-004 Start Date*: 2014-02-21
    Sponsor Name:Ethicon Inc
    Full Title: A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Sur...
    Medical condition: subjects undergoing major aortic surgery, including ascending, arch, or descending aorta replacement, requiring adjunctive support for hemostasis at the anastomotic suture line
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000434-34 Sponsor Protocol Number: HEM-01-17 Start Date*: 2020-06-18
    Sponsor Name:Sealantium Medical Ltd.
    Full Title: A Phase I/II, randomized, prospective, controlled, multi-center, open-label, two arm study evaluating the safety and preliminary efficacy of sFilm-FS in controlling liver bleeding during elective s...
    Medical condition: Open hepatic surgery, with presence of an target bleeding site (TBS).
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10067440 Hemostasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004489-24 Sponsor Protocol Number: IG1405 Start Date*: 2018-09-13
    Sponsor Name:Instituto Grifols, S.A
    Full Title: A Prospective, Randomised, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis dur...
    Medical condition: Treatment of haemorrage during surgery
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-003122-28 Sponsor Protocol Number: ArgLepi-2006 Start Date*: 2008-12-19
    Sponsor Name:Heinrich-Heine-Universität Düsseldorf
    Full Title: Argatroban versus Lepirudin in Critically Ill Patients
    Medical condition: Critically ill patients are usually treated with heparin for anticoagulation. A serious complication of heparin therapy is heparin-induced thrombocytopenia type II (HIT). Patients with HIT have t...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062506 Heparin-induced thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004009-37 Sponsor Protocol Number: MD2021.01 Start Date*: 2021-11-05
    Sponsor Name:Prothya Biosolutions BV
    Full Title: A Phase 1/2 study of the dose-response in pharmacodynamics and safety of prothrombin complex concentrate Cofact in healthy subjects under vitamin K antagonist anticoagulation
    Medical condition: Treatment of bleeding and perioperative prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10005103 Bleeding LLT
    21.0 10042613 - Surgical and medical procedures 10036898 Prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002204-24 Sponsor Protocol Number: 1160.203 Start Date*: 2014-12-17
    Sponsor Name:University Medical Center Groningen
    Full Title: REVERSAL OF ANTICOAGULANT EFFECT OF DABIGATRAN® BY PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX®) ASSESSED WITH A NOVEL METHOD OF BLOOD LOSS MEASUREMENT
    Medical condition: Healthy male volunteers. Study assessing the effect of a single 50IU/Kg dose of Beriplex on the anticoagulant effect of Dabigatran. This is of interest when rapid reversal of its effect is mandate...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002345-38 Sponsor Protocol Number: 12/0033/CTU/IMM/001 Start Date*: 2012-10-30
    Sponsor Name:University College London
    Full Title: A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Medical condition: Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003401-26 Sponsor Protocol Number: 400-12-006 Start Date*: 2014-05-16
    Sponsor Name:Ethicon Inc.
    Full Title: A Prospective, Randomized, Controlled, Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Hemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non‐Cardiac) Surgery in Pediatric P...
    Medical condition: Abdominal, Retroperitoneal, Pelvic or Thoracic (Non‐Cardiac) Surgery
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018723-26 Sponsor Protocol Number: 1160.86 Start Date*: 2010-07-15
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: An open label, non-comparative, pharmacokinetic and pharmacodynamic study to evaluate the effect of Dabigatran Etexilate on coagulation parameters including a calibrated thrombin time test in patie...
    Medical condition: Primary VTE prevention in patients with moderate renal impairment (Creatinine Clearance 30-50 ml/min) following total hip or knee replacement surgery
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-019427-58 Sponsor Protocol Number: 400-10-001 Start Date*: 2010-09-08
    Sponsor Name:Omrix Biopharmaceuticals Ltd
    Full Title: A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
    Medical condition: Subjects undergoing elective, open, hepatic surgery during which a resection plane is created and wherein an appropriate Target Bleeding Site is identified.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068093 Gastrointestinal surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003557-24 Sponsor Protocol Number: 400-12-004 Start Date*: 2014-04-02
    Sponsor Name:Ethicon Inc
    Full Title: A Prospective, Randomised, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST® Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During O...
    Medical condition: Mild or moderate hepatic parenchyma or soft tissue bleeding during open, abdominal, retroperitoneal, pelvic and thoracic (non-cardiac) surgery
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002535-24 Sponsor Protocol Number: BIOS-13-005 Start Date*: 2013-09-20
    Sponsor Name:Ethicon Inc., a Johnson & Johnson Co.
    Full Title: A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST™ Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery
    Medical condition: Subjects undergoing elective, open, hepatic surgery during which a resection plane is created and wherein an appropriate Target Bleeding Site is identified
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001456-34 Sponsor Protocol Number: ArgatrobanECMO_1.2 Start Date*: 2021-07-08
    Sponsor Name:Medical University of Vienna
    Full Title: A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)
    Medical condition: patients requiring treatment with extracorporeal membrane oxygenation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-005028-42 Sponsor Protocol Number: TC-019-IN Start Date*: 2006-03-03
    Sponsor Name:Nycomed Danmark ApS
    Full Title: A prospective, multi-centre, phase III-b study of TachoSil in paediatric patients scheduled for resection of the liver with or without segmental liver transplantation
    Medical condition: Paediatric patients (age above 4 weeks and below 6 years) undergoing surgical resection of the liver with or without segmental liver transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003556-39 Sponsor Protocol Number: DARINA Start Date*: 2012-06-05
    Sponsor Name:Martini Hospital Groningen
    Full Title: A randomized pilot study comparing the safety of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after knee arthroplasty surgery. DARINA
    Medical condition: After total knee arthroplasty (TKA) surgery, patients are at risk to develop venous thromboembolism (VTE). Two novel agents, dabigatran and rivaroxaban, recently gained market authorisation for pre...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001265-17 Sponsor Protocol Number: 3.0 Start Date*: 2018-08-07
    Sponsor Name:Turku University Central Hospital
    Full Title: Relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis (EdoRot).
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004357-13 Sponsor Protocol Number: CTH201401 Start Date*: 2015-03-18
    Sponsor Name:Odense University Hospital
    Full Title: Coagaulation in patients with atrial fibrillation: The effect of dabigatran
    Medical condition: Atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10071667 Persistent atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018480-42 Sponsor Protocol Number: 550904 Start Date*: 2010-11-12
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A RANDOMIZED, CONTROLLED, MULTICENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIBRIN SEALANT VH S/D 500 S-APR (TISSEEL) FOR HEMOSTASIS IN SUBJECTS UNDERGOING HEPATIC RESECTION
    Medical condition: Hemostasis in hepatic resection
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10060663 Surgical hemostasis LLT
    13.1 10042613 - Surgical and medical procedures 10067440 Hemostasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 02:10:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA